kalkitoxin and Breast-Neoplasms

kalkitoxin has been researched along with Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for kalkitoxin and Breast-Neoplasms

ArticleYear
Kalkitoxin inhibits angiogenesis, disrupts cellular hypoxic signaling, and blocks mitochondrial electron transport in tumor cells.
    Marine drugs, 2015, Mar-20, Volume: 13, Issue:3

    The biologically active lipopeptide kalkitoxin was previously isolated from the marine cyanobacterium Moorea producens (Lyngbya majuscula). Kalkitoxin exhibited N-methyl-D-aspartate (NMDA)-mediated neurotoxicity and acted as an inhibitory ligand for voltage-sensitive sodium channels in cultured rat cerebellar granule neurons. Subsequent studies revealed that kalkitoxin generated a delayed form of colon tumor cell cytotoxicity in 7-day clonogenic cell survival assays. Cell line- and exposure time-dependent cytostatic/cytotoxic effects were previously observed with mitochondria-targeted inhibitors of hypoxia-inducible factor-1 (HIF-1). The transcription factor HIF-1 functions as a key regulator of oxygen homeostasis. Therefore, we investigated the ability of kalkitoxin to inhibit hypoxic signaling in human tumor cell lines. Kalkitoxin potently and selectively inhibited hypoxia-induced activation of HIF-1 in T47D breast tumor cells (IC50 5.6 nM). Mechanistic studies revealed that kalkitoxin inhibits HIF-1 activation by suppressing mitochondrial oxygen consumption at electron transport chain (ETC) complex I (NADH-ubiquinone oxidoreductase). Further studies indicate that kalkitoxin targets tumor angiogenesis by blocking the induction of angiogenic factors (i.e., VEGF) in tumor cells.

    Topics: Angiogenesis Inhibitors; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Electron Transport Complex I; Female; Humans; Hypoxia-Inducible Factor 1; Inhibitory Concentration 50; Lipids; Mitochondria; Neovascularization, Pathologic; Signal Transduction; Thiazoles; Vascular Endothelial Growth Factor A

2015